Loading...
01/11 11:08
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call revealed several concerning factors: a decline in adjusted EPS guidance due to tariff impacts, a reduction in free cash flow expectations, and anticipated negative sales performance in China. Although revenue showed growth, the financial health is affected by tariffs and declining margins. The Q&A highlighted uncertainties in tariff impacts and management's unclear responses. Despite a positive share repurchase plan, the overall sentiment is negative due to financial guidance cuts and tariff-related challenges.
Revenue $4.8 billion, up 4% year-over-year, driven by strong execution and high-single-digit growth in the U.S. market.
Service Revenue Grew 3% year-over-year.
Product Revenue Increased by 2% year-over-year.
Organic Orders Growth Up 10% year-over-year, the highest since the company's spin-off, reflecting healthy underlying market demand.
Book-to-Bill Ratio 1.09 times, indicating strong order intake relative to revenue.
Backlog $20.6 billion, up $1.9 billion year-over-year and $800 million sequentially.
Adjusted EBIT Margin 15%, up 30 basis points year-over-year, due to volume and productivity improvements.
Adjusted EPS $1.01, up 12% year-over-year.
Free Cash Flow $98 million, down $175 million year-over-year, primarily due to timing of employee compensation payments and inventory build.
Adjusted Gross Margin Expanded 80 basis points year-over-year, driven by increased volume and higher margin new products.
R&D Investment 7% of sales, increasing 6% year-over-year.
Pharmaceutical Diagnostics Revenue Growth 8% year-over-year organic growth with EBIT margin above 32%.
Debt Repayment $250 million repaid in the first quarter.
Share Repurchase Program Authorized $1 billion share repurchase program.
Tariff Impact on Adjusted EPS Estimated at $0.80 per share, contributing to a total adjusted EPS guidance of $3.90 to $4.10, representing a 9% to 13% decline year-over-year.
Free Cash Flow Guidance Expected to be at least $1.2 billion for the full-year, down from previous expectations of at least $1.75 billion.
New Product Launches: Launched Flyrcado, a novel PET myocardial perfusion imaging agent for coronary artery disease detection, with CMS pass-through pricing.
New Imaging System: Introduced Revolution Vibe, a dedicated cardiac CT system for various cardiac tests.
Market Expansion: Gained market share in several competitive markets, particularly in the U.S. with strong orders growth.
New Agreements: Announced agreement with St. Luke's University Health Network to drive further growth.
Operational Efficiency: Implemented a new lean management system in imaging, reducing past-due backlog by over $25 million.
R&D Investment: Invested 7% of sales in R&D, increasing 6% year-over-year to advance innovation initiatives.
Strategic Shift: Transitioning from an imaging and equipment company to a healthcare solutions provider.
Leadership Change: Welcoming Jeannette Bankes as the new CEO of patient care solutions.
Tariff Impact: The estimated gross impact of tariffs is approximately $1.75 per share, with a net incremental impact of about $0.80 per share after mitigation actions.
Regulatory Issues: The company is adjusting its 2025 guidance due to the impact of tariffs, particularly from U.S.-China trade relations and other international tariffs.
Supply Chain Challenges: The company is actively working on optimizing its supply chain to mitigate tariff impacts, which includes product and component moves that may take longer to execute.
Economic Factors: The company anticipates a negative sales performance in China for the first half of 2025, with a low-single-digit decline expected for the year.
Free Cash Flow: Free cash flow is expected to be at least $1.2 billion for the full year, down from a prior expectation of at least $1.75 billion due to tariff payments.
Adjusted EPS Guidance: Adjusted EPS is now expected to be between $3.90 and $4.10 for the full year, reflecting a 9% to 13% decline year-over-year, impacted by tariffs.
Innovation Pipeline: GE HealthCare is focused on advancing its innovation initiatives, including the launch of new products such as Flyrcado, a novel PET myocardial perfusion imaging agent, and a dedicated cardiac CT system, Revolution Vibe.
Market Expansion: The company is strengthening its market presence and has secured significant orders, including from Sutter Health and St. Luke's University Health Network.
Operational Efficiency: GE HealthCare is implementing productivity initiatives, including a new lean management system to improve backlog conversion and customer satisfaction.
Leadership Changes: Jeannette Bankes will join as the new CEO of patient care solutions, bringing over 30 years of experience in MedTech.
2025 Revenue Growth: The company expects organic revenue growth in the range of 2% to 3% for the full year 2025.
Adjusted EBIT Margin: Forecasted adjusted EBIT margin is now between 14.2% and 14.4%, down from previous guidance of 16.7% to 16.8%.
Adjusted EPS Guidance: Adjusted EPS is now expected to be between $3.90 and $4.10, reflecting a 9% to 13% decline year-over-year.
Free Cash Flow: Free cash flow is expected to be at least $1.2 billion for the full year, down from prior expectations of at least $1.75 billion.
Tariff Impact: The estimated impact of tariffs on adjusted EPS is approximately $0.85, with an incremental negative impact of $475 million on adjusted EBIT.
Share Repurchase Program Authorization: GE HealthCare announced a share repurchase program authorization from the Board of Directors of $1 billion.
The earnings call reveals strong financial metrics, optimistic guidance, and strategic advancements in nuclear medicine and AI integration, suggesting positive stock movement. Despite some uncertainties in tariff mitigation and competitive impact, raised guidance for revenue, EBIT margin, and EPS, alongside new product launches, supports a positive outlook.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
